Cadila Healthcare has reported results for the quarter ended June 30, 2011
The company’s net profit for the quarter has dipped by 23.01% at Rs 152.93 crore as compared to Rs 198.64 crore for the quarter ended June 30, 2010. Its total Income too has decreased by 1.07% to Rs 790.52 crore for the quarter under review from Rs 799.11 crore for the corresponding quarter of the previous year.
On Consolidated basis, the Group ‘s net profit has registered a gain of 15.38% at Rs 229.82 crore for the quarter ended June 30, 2011 as compared to Rs 199.18 crore for the quarter ended June 30, 2010. Its total Income has increased by 10.15% to Rs 1252 crore for the quarter from Rs 1136.65 crore for the similar quarter of the previous year.
Cadila Pharmaceuticals focuses on various areas, such as formulations (human & veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1530.00 |
Dr. Reddys Lab | 5802.00 |
Cipla | 1399.35 |
Zydus Lifesciences | 1051.90 |
Lupin | 1653.75 |
View more.. |